I.C.R. Santos, D.R. Daga, H.R. Frigeri, R.R. Réa, A.C.R. Almeida, E.M. Souza, F.O. Pedrosa, C.M.T. Fadel-Picheth and G. Picheth
Published June 15, 2010
Genet. Mol. Res. 9 (2): 1130-1135 (2010)
DOI 10.4238/vol9-2gmr817

About the authors
I.C.R. Santos, D.R. Daga, H.R. Frigeri, R.R. Réa, A.C.R. Almeida, E.M. Souza, F.O. Pedrosa, C.M.T. Fadel-Picheth and G. Picheth

Corresponding author
G. Picheth
E-mail: gpicheth@ufpr.br

ABSTRACT

The receptor for advanced glycation end products (RAGE or AGER) is a multiligand member of the immunoglobulin superfamily. RAGE is expressed in several tissues, including human myometrium, chorionic villi and placenta. Advanced glycation end products are the best studied ligands of RAGE; they have pro-inflammatory actions in human gestational tissues, increasing oxidative stress and the release of cytokines and prostaglandins. Winvestigated the association of RAGE gene promoter polymorphisms -429T>C (rs1800625) and -374T>A (rs1800624) with gestational diabetes. A sample of 750 unrelated European origin pregnant Brazilian women were classified as nondiabetic (control group, N = 600) or having gestational diabetes (N = 150) according to American Diabetes Association 2009 criteria. Genotyping was performed by PCR-RFLP. The frequencies of the rare alleles -429C (6.3 versus 9.1%) and -374A (26 versus 30%) were not significantly different between the gestational diabetes patients and healthy pregnant women. Also, the -429T>C and -374T>A polymorphisms were not associated with body mass index, lipid profile, fasting glycemia, HbA1C, or insulin requirement. We found that functional promoter polymorphisms of the RAGE gene were not associated with gestational diabetes or its complications in these Euro-Brazilian patients.

Key words: Gestational diabetes; Single nucleotide polymorphisms; Genetic polymorphisms; RAGE; AGER